A recent study indicates that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who stop conventional lifestyle plans.
Research printed in a leading health publication shows that while obese people frequently drop about a fifth of their total mass while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing such treatments must be aware of the potential of quick rebound weight gain when the treatment ends," warns lead investigator Dr. Susan Jebb.
This pace of recovery suggests a reversion to original mass in about a year and a half.
Weighing Approaches
The study, which looked at 37 of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with other pills.
The team note that individuals who shed pounds through lifestyle changes alone generally experience a less rapid weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Fast Rebound
Doctors believe the way of the drugs explains the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its own natural hormone, and could reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement leads to hunger is unsuppressed, making excessive eating far more likely."
An Ongoing Condition?
The NHS suggest the jabs for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, given the significant potential of relapse, the therapy is often life-long.
This opinion is reinforced by pharmaceutical companies, who state that the results "underscore the long-term character of obesity," comparing it to managing conditions like diabetes.
Patient Experiences
Users who have stopped the medication explain a sudden return of hunger.
"It felt as if a switch flipping and I was suddenly extremely hungry," described an individual.
The struggle is compounded if patients have not developed permanent dietary or behavioural changes during therapy.
Growing Use
Recent estimates show that a significant number of people in the UK have tried these injections in the past year, with desire continuing to grow.
- Adoption is higher among women compared to males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, experts caution that while these medications are potent agents for shedding pounds, they are not a permanent solution and lasting health benefits relies on integrated behavioural changes.
